Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of iPSC-derived Platelets (RBT101) in Thrombocytopenia Post-HSCT
NCT07905144Phase 1Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2026
- Primary completion
- Oct 2027
01
Overview
Phase 1, open-label trial of RBT-101 in Thrombocytopenia (3 arms), sponsored by Ruijin Hospital. Primary endpoint: Adverse Events at 28 days. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
RBT-101
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT07905144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07905144.